26 A Nomogram for Predicting High Axillary Disease Burden in Patients With Localized HR+, HER2-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ByNeha Kalakuntla,Yulun Liu,Holly Grace,Marilyn Leitch,Asal Rahimi,Mona Arbab,Narine Wandrey,Deborah Farr, MD,Heather McArthur, MD, MPH,Sunati Sahoo,Stephen Seiler,Prasanna Alluri In 167 patients with HR+/HER2− breast cancer after neoadjuvant chemotherapy, lymphovascular invasion, number of positive sentinel nodes, and >50% positive sentinel nodes were the strongest predictors of high axillary burden; a nomogram was developed to guide axillary management decisions.
